Lyka Labs Q2 FY26 results show strong revenue and PAT growth
LYKALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.5 pts less than Nifty Microcap 250 and 2.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lyka Labs Q2 FY26 results show strong growth. Standalone revenue from operations rose to 6,214.68 lakhs (Q2 FY25: 4,115.51). H1 FY26 total income was 13,704.09 lakhs, about 90 percent higher YoY. Q2 PAT jumped to 422.24 lakhs (Q2 FY25: 81.42). H1 PAT turned positive at 822.72 lakhs versus a loss of 281.27 lakhs. Consolidated results mirrored this trend. Auditor gave an unqualified opinion. An ECL provision of 484.03 lakhs was booked on international trade receivables.
Strong quarterly growth and turnaround from loss signal improving business. Watch for recovery in international receivables after ECL provision.